Combating the neglected consequences of the opioid crisis
By: Mah Noor, PharmD Candidate c/o 2021 Although the opioid crisis began in the late 1990s, there has been a…
Overview of the use of neuromuscular blocking agents in surgery and critical care and their reversal agents: sugammadex (Bridion®) and neostigmine methylsulfate (Bloxiverz®)
By: Joseph DiPaola (PharmD Candidate c/o 2022), Nishanth Viswanath (PharmD Candidate c/o 2022) Neuromuscular blocking agents (NMBAs) are drugs…
COVID-19: The 2019 novel coronavirus
By: Darien Lee, PharmD Candidate c/o 2021 Wuhan, the most populous city in Central China, has a population of…
Basal-bolus vs. sliding-scale insulin in hospitalized patients: assessment of advantages and disadvantages
By: Maria Sedky Saad (PharmD Candidate c/o 2021), Shivani Shah (PharmD Candidate c/o 2021) Hyperglycemia is a common condition…
Treatment of iron deficiency anemia
By: Maryam Sekhery, PharmD Candidate c/o 2020 According to the World Health Organization, anemia is defined as having a…
FDA approves romosozumab (Evenity®) for the treatment of postmenopausal osteoporosis
By: Michael Lim, PharmD Candidate c/o 2020 Osteoporosis is a bone disease affecting nearly ten million people in the…
Residency Starter Guide
By: Yao Jiang, PharmD (St. John’s University c/o 2019) “Do you want to do a residency?” a senior pharmacy…
The rising cost of insulin
By: Daniela Farzadfar, PharmD Candidate c/o 2020 Over 30 million Americans are currently living with diabetes. According to the…
Food and Drug Administration approves lofexidine (LucemyraTM): the first non-addictive opioid withdrawal therapy in the United States
By: Evanthia Siozios, PharmD Candidate c/o 2020 Anxiety, nausea, muscle pain, insomnia are some of the most common withdrawal…
The “Netflix” approach to hepatitis C drugs
By: Michael Lim, PharmD Candidate c/o 2020 In a February 2019 Senate Finance Committee hearing, executives from major pharmaceutical…